Radius Health (NASDAQ:RDUS) has been assigned a $58.00 price target by equities research analysts at Cantor Fitzgerald in a research report issued on Friday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 102.37% from the company’s current price.

RDUS has been the topic of a number of other reports. Maxim Group reissued a “positive” rating on shares of Radius Health in a report on Friday, September 29th. They noted that the move was a valuation call. ValuEngine raised Radius Health from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st. BidaskClub lowered Radius Health from a “sell” rating to a “strong sell” rating in a report on Thursday, December 7th. Goldman Sachs Group reaffirmed a “neutral” rating and issued a $45.00 price objective on shares of Radius Health in a report on Friday, October 6th. Finally, Jefferies Group decreased their price objective on Radius Health from $38.00 to $31.00 and set a “hold” rating on the stock in a report on Friday, November 3rd. Three research analysts have rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $48.00.

Radius Health (RDUS) traded down $0.96 during mid-day trading on Friday, hitting $28.66. The company had a trading volume of 1,100,600 shares, compared to its average volume of 976,504. The company has a current ratio of 12.87, a quick ratio of 12.79 and a debt-to-equity ratio of 0.53. Radius Health has a 1-year low of $24.66 and a 1-year high of $49.16.

Radius Health (NASDAQ:RDUS) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.03). The company had revenue of $13.50 million during the quarter, compared to analyst estimates of $6.90 million. During the same quarter in the previous year, the firm earned ($1.07) earnings per share. equities analysts forecast that Radius Health will post -5.57 EPS for the current year.

In other news, major shareholder Growth N. V. Biotech acquired 50,000 shares of the firm’s stock in a transaction on Wednesday, October 25th. The shares were purchased at an average cost of $32.85 per share, with a total value of $1,642,500.00. Following the acquisition, the insider now directly owns 5,548,799 shares in the company, valued at approximately $182,278,047.15. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Jesper Hoiland acquired 6,800 shares of the firm’s stock in a transaction on Tuesday, November 7th. The stock was purchased at an average cost of $29.04 per share, for a total transaction of $197,472.00. Following the completion of the acquisition, the insider now owns 12,900 shares in the company, valued at $374,616. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 158,578 shares of company stock worth $4,659,916. Insiders own 15.00% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. BB Biotech AG lifted its position in shares of Radius Health by 11.0% during the 2nd quarter. BB Biotech AG now owns 5,038,799 shares of the biopharmaceutical company’s stock valued at $227,905,000 after acquiring an additional 498,400 shares during the period. Farallon Capital Management LLC lifted its position in shares of Radius Health by 18.3% during the 2nd quarter. Farallon Capital Management LLC now owns 3,686,300 shares of the biopharmaceutical company’s stock valued at $166,731,000 after acquiring an additional 569,300 shares during the period. Vanguard Group Inc. lifted its position in shares of Radius Health by 4.5% during the 2nd quarter. Vanguard Group Inc. now owns 3,145,717 shares of the biopharmaceutical company’s stock valued at $142,281,000 after acquiring an additional 135,071 shares during the period. BlackRock Inc. lifted its position in shares of Radius Health by 10.0% during the 2nd quarter. BlackRock Inc. now owns 2,893,641 shares of the biopharmaceutical company’s stock valued at $130,881,000 after acquiring an additional 262,896 shares during the period. Finally, State Street Corp lifted its position in shares of Radius Health by 12.9% during the 2nd quarter. State Street Corp now owns 1,867,531 shares of the biopharmaceutical company’s stock valued at $84,473,000 after acquiring an additional 213,399 shares during the period.

TRADEMARK VIOLATION NOTICE: “Radius Health (RDUS) Given a $58.00 Price Target by Cantor Fitzgerald Analysts” was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/12/15/radius-health-rdus-given-a-58-00-price-target-by-cantor-fitzgerald-analysts-2.html.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.